Streetbeat News

Revenues

CTAS

Cintas (NASDAQ:CTAS) has been evaluated by 11 analysts over the past three months, showing a range of opinions from bullish to bearish. The average 12-month price target has decreased by 7.93% to $662.0. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Cintas is a leading provider of uniforms and facility services, with strong financial metrics such as revenue growth, net margin, and return on equity.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 5:01 pm

HIMS

Hims & Hers Health (NYSE:HIMS) has received varied analyst ratings over the past three months, with a mix of bullish and indifferent sentiments. Analysts have set a 12-month average price target of $21.75, indicating a 31.26% increase from the previous target. The company has shown strong financial performance, with significant revenue growth and profitability metrics exceeding industry averages.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 5:00 pm

NVDA

ORCL

Oracle's CloudWorld conference impressed analysts, leading to increased price targets and positive outlooks on its AI and cloud growth. Analysts highlighted Oracle's resilient revenue stream, cloud leadership, and ambitious revenue targets, projecting strong long-term growth.

Portfolio Pulse from Surbhi Jain

September 13, 2024 | 4:54 pm

SHEL

Shell is increasing production at its Appomattox, Mars, Vito, Ursa, and Olympus facilities after resolving downstream issues.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 4:44 pm

AEM

Agnico Eagle Mines (NYSE:AEM) has delivered an average annual return of 9.52% over the past 20 years, outperforming the market by 1.17% annually. A $100 investment in AEM 20 years ago would now be worth $636.72.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:32 pm

THC

Tenet Healthcare (NYSE:THC) has significantly outperformed the market over the past 5 years, with an average annual return of 45.31%. A $100 investment in THC 5 years ago would now be worth $634.25, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:32 pm

BA

Boeing's CFO stated at Morgan Stanley's 12th Annual Laguna Conference that it is too early to predict the company's free cash flow for 2024 and 2025.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 4:10 pm

EOLS

Evolus (NASDAQ:EOLS) has received diverse analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased by 4.6% to $22.75. Analysts have adjusted their ratings and price targets, reflecting positive sentiment. Evolus, a performance beauty company, has shown strong revenue growth but faces challenges with high debt and low ROE and ROA.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:01 pm

U

Unity Software (NYSE:U) has received mixed analyst ratings, with a recent decrease in average price target by 17.29%. Analysts have provided a range of price targets from $10.00 to $33.50. The company faces challenges with declining revenue, low net margins, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:01 pm

BA

Boeing's CFO highlighted significant supply chain constraints affecting the aerospace industry, particularly impacting widebody aircraft deliveries. This was discussed at Morgan Stanley's 12th Annual Laguna Conference 2024.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 4:01 pm